论文部分内容阅读
本文作者报道应用α_2-干扰素(α_2-IFN)治疗进展期特发性骨髓纤维化(IM)。5例患者骨髓活检证实为IM,所有患者均需常规输注红细胞和/或患症状性脾肿大,年龄为43 74岁(中位数64岁)。诊断后病程为10-72个月(中位数48个月)。5例患者每月须输注红细胞2-8.4个。1例在IFN治疗前5个月已行脾切除,其余均有症状性脾肿大。治疗前检查包括体检、骨髓活检、全血计数、肝和肾功能指标,以及血钙、尿酸、血清电解质和乳酸脱氢酶水平。在IFN治疗期间至少每周做1次体检、全血计数和白细胞分类。治疗用人重组α_2-IFN由BII提供。比活性为1×10~8U/mg蛋白质。1ml含2×10~6单位α_2-IFN。4例患者给予1×0~6U,均每日1次皮下注射。结果表明,IFN疗程为1至6个月(中位数3.2
The authors report the use of α 2-interferon (α 2-IFN) in the treatment of idiopathic myelofibrosis (IM). Five patients had a bone marrow biopsy confirmed as IM, all of whom had regular red blood cell transfusions and / or symptomatic splenomegaly, aged 43-74 years (median, 64 years). After the diagnosis of disease duration of 10-72 months (median 48 months). Five patients had transfused erythrocytes 2-8.4 per month. One patient had splenectomy 5 months prior to IFN treatment and the rest had symptomatic splenomegaly. Pre-treatment tests include physical examinations, bone marrow biopsies, whole blood counts, liver and kidney function parameters, and serum calcium, uric acid, serum electrolytes, and lactate dehydrogenase levels. At least one checkup, whole blood count, and white blood cell classification were performed during the IFN treatment. Therapeutic human recombinant α_2-IFN is provided by BII. Specific activity of 1 × 10 ~ 8U / mg protein. 1ml contains 2 × 10 ~ 6 units α_2-IFN. 4 patients were given 1 × 0 ~ 6U, 1 times daily subcutaneous injection. The results showed that IFN treatment for 1 to 6 months (median 3.2